Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.66B |
| Gross Profit (TTM) | $1.27B |
| EBITDA | $1.05B |
| Operating Margin | 59.80% |
| Return on Equity | 173.70% |
| Return on Assets | 25.50% |
| Revenue/Share (TTM) | $14.15 |
| Book Value | $1.26 |
| Price-to-Book | 77.99 |
| Price-to-Sales (TTM) | 7.03 |
| EV/Revenue | 7.88 |
| EV/EBITDA | 18.25 |
| Quarterly Earnings Growth (YoY) | 42.90% |
| Quarterly Revenue Growth (YoY) | 47.70% |
| Shares Outstanding | $113.50M |
| Float | $112.16M |
| % Insiders | 1.11% |
| % Institutions | 112.78% |
Volatility is currently expanding
SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings more than 20 years of executive leadership across the biotechnology and pharmaceutical industries, with deep expertise in operations, manufacturing, and supply chain management.
Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here is how Halozyme Therapeutics (HALO) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.
Total Revenue Increased 48% YOY to $481 million Royalty Revenue Increased 50% YOY to $308 million Raises 2026 Financial Guidance Ranges: Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 37% Royalty Revenue of $1.220 - $1.245 billion, YOY Growth of 41% - 43% Adjusted EBITDA of $1.225 - $1.280 billion, YOY Growth of 86% - 95% 1 Non-GAAP Diluted EPS of $8.65 - $9.00, YOY Growth of 108% - 117% 1 Signed Five New ENHANZE ® and Hypercon ™ Collaboration Agreements YTD 2026, Exceeding Goal of Three for Full Year 2026 SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2026, and provided an update on its recent corporate activities. "We delivered another quarter of strong performance, with multiple proof points demonstrating the attractive features of ENHANZE as a compounding platform engine: repeatability of success, scalability, diversification and durability of revenues," said Dr. Helen Torley, President and Chief Executive Officer.
Halozyme (HALO) has delivered ~134% price appreciation since my prior 'Buy' rating in 06/2023. I evaluate whether HALO can sustain its strong growth trajectory or is due for a period of consolidation. The investment thesis centers on HALO's robust royalty revenue and product income as key growth drivers.
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of trading. Halozyme will host a conference call on Thursday, August 6, 2026 at 1:30pm PT/4:30pm ET to discuss the results.
Halozyme Therapeutics, Inc. (HALO) shares gain 539% since first Big Money outlier inflow signal in March 2014.
Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), utilizing Halozyme's proprietary ENHANZE® drug delivery technology. The collaboration will focus on the potential for ENHANZE® to strengthen the subcutaneous formulation currently in development for INCA033989, with the goal of enabling more convenient delivery and dosing regimens that may improve the treatment experience.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HALO and any ticker you trade — then tracks every position and per-strategy win rate.
